Loading…
Prothena Corporation plc is projected to rise to $10.72 by 2027, a +16% move from its current price of $9.24. PRTA is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $9.00 | $9.24 | $9.50 | +0.04% |
| Jul 14 | $8.90 | $9.25 | $9.61 | +0.07% |
| Jul 15 | $8.83 | $9.25 | $9.69 | +0.11% |
| Jul 16 | $8.77 | $9.25 | $9.76 | +0.14% |
| Jul 17 | $8.72 | $9.26 | $9.83 | +0.18% |
| Jul 18 | $8.67 | $9.26 | $9.89 | +0.22% |
| Jul 19 | $8.63 | $9.26 | $9.95 | +0.25% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $8.63 | $9.26 | $9.95 | +0.25% |
| Week 2 | $8.40 | $9.29 | $10.27 | +0.50% |
| Week 3 | $8.23 | $9.31 | $10.53 | +0.76% |
| Week 4 | $8.10 | $9.33 | $10.76 | +1.01% |
| Week 5 | $7.98 | $9.36 | $10.97 | +1.26% |
| Week 6 | $7.88 | $9.38 | $11.17 | +1.52% |
| Week 7 | $7.79 | $9.40 | $11.35 | +1.77% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Prothena Corporation plc is a late-stage clinical biotechnology company focused on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies; Coramitug, an investigational antibody, which is in Phase 3 clinical trial for the treatment of transthyretin amyloidosis; BMS-986446, an anti-tau antibody which is in Phase 2 clinical trial to treat Alzheimer's disease; PRX019, an investigational antibody which is in Phase 1 clinical trial for the treatment of neurodegenerative diseases; and PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease. In addition, it develops discovery- and late-preclinical-stage programs include TDP-43 CYTOPE for the treatment of amyotrophic lateral sclerosis; PRX012, a next-generation anti-Aß antibody which is in phase 1 clinical trial to treat Alzheimer's disease; and PRX012-TfR, a preclinical program for the treatment of Alzheimer's disease.
It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43.
Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.
PRTA is a biotechnology company operating in the healthcare sector. The current price is $9.14 per share. The company has a market capitalization of $478.51M and is ranked 3068 by market capitalization.
The price outlook across the year-by-year forecast shows a bullish trajectory, with the average forecast price rising from $9.14 in 2026 to $12.62 in 2030 and to $51.52 on average by 2050, while the maximums project up to $94.70 and the ROIs rise to 463.7% by 2050. These figures imply meaningful upside over the long term, albeit with the inherent uncertainty of future market conditions.
A major floor 26.0% below — a decisive break under it would weaken the trend.
The nearest floor, 14.4% below — buyers have tended to step in here.
The nearest ceiling, 10.2% above — a clean break opens room to run.
A major ceiling 24.6% above — clearing it would confirm fresh momentum.
Key PRTA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of PRTA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $9.58 | Sell | $9.54 | Sell |
| MA 10 | $9.70 | Sell | $9.53 | Sell |
| MA 20 | $9.24 | Buy | $9.43 | Sell |
| MA 50 | $9.56 | Sell | $9.49 | Sell |
| MA 100 | $9.64 | Sell | $9.56 | Sell |
| MA 200 | $9.73 | Sell | $9.78 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 47.17 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | 0.65 | Neutral |
| Williams %R (14) | -89.66 | Info |
| MACD (12,26,9) | 0.04 | Buy |
| ROC (12) | -3.25 | Sell |
| Bollinger %B (20,2) | 0.50 | Neutral |
| Stochastic %K (14) | 10.34 | Buy |
| TRIX (15) | 0.06 | Buy |
| Awesome (5,34) | 0.32 | Buy |
| Ultimate (7,14,28) | 39.74 | Neutral |
| Momentum (10) | -0.03 | Sell |
| Aroon Osc (25) | 44.00 | Buy |
| Hull MA (9) | 9.58 | Sell |
| ADX (14) | 13.43 | Neutral |
| ATR (14) | 0.25 | Info |
The 30-day technical picture is Neutral. The RSI(14) is 50, indicating balanced momentum. The 50-day simple moving average is $9.56 and the 200-day simple moving average is $9.73, suggesting the price is near both key averages.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $7.91 | $9.24 | $12.68 | 0% | Neutral | |
| $8.54 | $10.72 | $14.21 | +16% | Neutral | |
| $9.13 | $11.77 | $16.19 | +27% | Bullish | |
| $8.89 | $11.72 | $16.59 | +27% | Bullish | |
| $9.47 | $12.75 | $18.48 | +38% | Bullish | |
| $10.29 | $14.11 | $20.89 | +53% | Bullish | |
| $11.15 | $15.54 | $23.45 | +68% | Bullish | |
| $13.60 | $19.26 | $29.56 | +108% | Bullish | |
| $14.16 | $20.36 | $31.73 | +120% | Bullish | |
| $13.34 | $19.46 | $30.79 | +111% | Bullish | |
| $19.43 | $30.27 | $50.90 | +228% | Bullish | |
| $29.86 | $52.07 | $95.71 | +464% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $7.91 | $9.24 | $11.15 | +0.00% |
| August 2026 | $7.90 | $9.32 | $11.29 | +0.88% |
| September 2026 | $8.04 | $9.55 | $11.69 | +2.43% |
| October 2026 | $8.41 | $10.05 | $12.42 | +5.29% |
| November 2026 | $8.48 | $10.19 | $12.69 | +1.35% |
| December 2026 | $8.38 | $10.11 | $12.68 | -0.78% |
Click any year to see its month-by-month PRTA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Prothena Corporation plc's 2026 outlook centres on $9.24, within a $7.91 to $12.68 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, PRTA could reach as high as $14.21, with a base case around $10.72 and support toward $8.54 — roughly +16% from $9.24. A consolidation phase looks the most probable path here.
Expect PRTA to range from $9.13 to $16.19 through 2028. The $11.77 average target implies a +27% move from current prices. That is up +10% on the projected 2027 average. Momentum favours further upside here.
The PRTA price prediction for 2029 points to an average of $11.72 (low $8.89, high $16.59) — a potential gain of +27% on today's $9.24. Buyers look set to stay in control over this stretch.
In 2030, PRTA is projected to trade between $9.47 and $18.48, averaging $12.75 — a potential gain of +38% from today's $9.24. That is up +9% on the projected 2029 average. Momentum favours further upside here.
Prothena Corporation plc's 2031 outlook centres on $14.11, within a $10.29 to $20.89 range. That is up +11% on the projected 2030 average. That marks a +53% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, PRTA could reach as high as $23.45, with a base case around $15.54 and support toward $11.15 — roughly +68% from $9.24. Momentum favours further upside here.
Expect PRTA to range from $13.60 to $29.56 through 2033. The $19.26 average target implies a +108% move from current prices. That is up +24% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The PRTA price prediction for 2034 points to an average of $20.36 (low $14.16, high $31.73) — a potential gain of +120% on today's $9.24. Momentum favours further upside here.
In 2035, PRTA is projected to trade between $13.34 and $30.79, averaging $19.46 — a potential gain of +111% from today's $9.24. That is -4% versus the projected 2034 average. Buyers look set to stay in control over this stretch.
Prothena Corporation plc's 2040 outlook centres on $30.27, within a $19.43 to $50.90 range. That is up +56% on the projected 2035 average. That marks a +228% change versus current levels. Momentum favours further upside here.
By 2050, PRTA could reach as high as $95.71, with a base case around $52.07 and support toward $29.86 — roughly +464% from $9.24. Buyers look set to stay in control over this stretch.
Investing $1,000 in PRTA today (≈ 108.225108 PRTA) could be worth
$5,635.61
+$4,635.61 (+464%) by 2050 · US Dollar
Based on the average projected PRTA price of $52.07 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in PRTAwould be worth at today's price.
$1,000 invested in PRTA on Jul 10, 2025 (≈ 152.206998 PRTA) would be worth
$1,406.39
+$406.39 (+40.6%) today · 1.41× · US Dollar
Based on a PRTA entry price of $6.57 vs. today's $9.24.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $9.69 | $953.56 | -4.6% |
| 1 month ago | $7.91 | $1,168.14 | +16.8% |
| 3 months ago | $10.5 | $880 | -12.0% |
| 6 months ago | $8.91 | $1,037.04 | +3.7% |
| 1 year ago | $6.57 | $1,406.39 | +40.6% |
| All time (5.0y) ago | $52.34 | $176.54 | -82.3% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our PRTA forecast.
Our base-case forecast reaches $18.00 around 2033.
Implied market cap at $18.00: $942.36M
The multi-year forecast shows a bullish trajectory with rising averages and ROIs. In 2026 the average is $9.14 with a 0% ROI. By 2027 the average rises to $10.61 with a 16.1% ROI, and by 2028 to $11.63 with a 27.3% ROI.
The 2029 forecast shows an average of $11.60 and a 26.9% ROI, advancing to 2030 with an average of $12.62 and a 38.1% ROI. The 2031–2035 period continues the uptrend with 2031 avg $13.94 (52.6% ROI), 2032 avg $15.39 (68.3% ROI), 2033 avg $19.07 (108.7% ROI), 2034 avg $20.12 (120.2% ROI), and 2035 avg $19.24 (110.5% ROI). In 2040 the forecast averages $29.93 with a 227.5% ROI, and by 2050 the average is $51.52 with a 463.7% ROI, while the 2050 low/high are $29.54/$94.70 respectively.
These figures depict an overall bullish path through 2050, though they remain estimates and are not guaranteed.
Tap a question to reveal the answer.
In 2030, the forecast shows an avg price of $12.62, with a min of $9.38 and a max of $18.30, and an ROI of 38.1%. The sentiment is BULLISH.
The forecast shows bullish sentiment from 2027 onward with rising average prices and ROIs, including 16.1% in 2027, 27.3% in 2028, 26.9% in 2029, 38.1% in 2030, and up to 463.7% by 2050, though these are estimates.
Yes—the forecast lists a max of $20.65 in 2031 and $23.22 in 2032.
Current price is $9.14 and market cap is $478.51M.
The 2050 forecast shows an avg price of $51.52 with a min of $29.54 and a max of $94.70, and an ROI of 463.7% with bullish sentiment.
Prothena Corporation plc Community Discussion
0Share your Prothena Corporation plc price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.